Fibrillin-1 gene mutations in a Chinese cohort with congenital ectopia lentis: spectrum and genotype-phenotype analysis

Zexu Chen, Tianhui Chen, Min Zhang, Jiahui Chen, Michael Deng, Jialei Zheng, Li-Na Lan, Yongxiang Jiang, Zexu Chen, Tianhui Chen, Min Zhang, Jiahui Chen, Michael Deng, Jialei Zheng, Li-Na Lan, Yongxiang Jiang

Abstract

Aims: To identify the mutation spectrum and genotype-phenotype correlations of fibrillin-1 (FBN1) mutations in a Chinese cohort with congenital ectopia lentis (EL).

Methods: Patients clinically suspected of congenital zonulopathy were screened using panel-based next-generation sequencing followed by multiplex ligation-dependent probe amplification. All the probands were subjected to thorough ocular examinations. Molecular and clinical data were integrated in pursuit of genotype-phenotype correlation.

Results: A total of 131 probands of FBN1 mutations from unrelated families were recruited. Around 65% of the probands were children younger than 9 years old. Overall, 110 distinct FBN1 mutations were identified, including 39 novel ones. The most at-risk regions were exons 13, 2, 6, 15, 24 and 33 in descending order of mutation frequency. The most prevalent mutation was c.184C>T (seven, 5.34%) in the coding sequence and c.5788+5G>A (three, 2.29%) in introns. Missense mutations were the most frequent type (103, 78.63%); half of which were distributed in the N-terminal regions (53, 51.46%). The majority of missense mutations were detected in one of the calcium-binding epidermal growth factor-like domains (62, 60.19%), and 39 (62.90%) of them were substitutions of conserved cysteine residues. Microspherophakia (MSP) was found in 15 patients (11.45%). Mutations in the middle region (exons 22-42), especially exon 26, had higher risks of combined MSP (OR, 5.51 (95% CI 1.364 to 22.274), p=0.017).

Conclusions: This study extended the knowledge of the FBN1 mutation spectrum and provided novel insights into its clinical correlation regarding EL and MSP in the Chinese population.

Keywords: genetics; lens and zonules.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Photos of congenital zonulopathy caused by fibrillin-1 mutations. (A) One eye of a patient (c.1709G>C) with EL and smooth lens edge. The lens was dislocated superior nasally. (B) One eye of a patient (c.3476G>T) with EL and MSP. The lens was thicker, and the entire equator was visible when the pupil was fully dilated. The superior equator is hidden because of combined EL. (C) One eye of a patient (c.290C>G) with coloboma lentis. A notch in the lens tissue at the equator was observed inferior temporally. (D) One eye of a patient (c.5885_5895del) with EL and an irregular lens edge at the temporal side. EL, ectopia lentis; MSP, microspherophakia.
Figure 2
Figure 2
Structural distribution of fibrillin-1 (FBN1) mutations (including recurrent mutations). (A) Frequency of FBN1 mutations per exon and the corresponding N-terminal (exons 1–21), middle (exons 22–42) and C-terminal (exons 43–65) regions. (B) Frequency of FBN1 mutations per intron. (C) Frequency of FBN1 mutations per amino acid and the corresponding protein domains. Hotspots are noted.cb, calcium binding; COOH; carboxyl; EGF, epidermal growth factor; LTBP, latent transforming growth factor β binding protein; NH2, amino; TGFBP, transforming growth factor β binding protein.
Figure 3
Figure 3
Genetic analyses of the fibrillin-1 (FBN1) mutations identified in 131 probands with zonulopathy. (A) Proportions of FBN1 mutations of all probands classified as missense mutations, frameshift mutations, nonsense mutations, splicing mutations, in-frame deletions or insertions, complex mutations and intragenic deletion/duplication. (B) Proportions of FBN1 missense mutation amino acid changes classified as cysteine (Cys)-creating, Cys-eliminating and changes involving other amino acids. (C) Proportions of FBN1 missense mutations mapped to coding sequences in the N-terminal (exons 1–21), middle (exons 22–42) and C-terminal (exons 43–65) regions. (D) Proportions of FBN1 missense mutations mapped to EGF-like domain, cb-EGF-like domain, TGFBP domain, 4-Cys motif LTBP-like domain, hybrid module and other protein domains. (E) Heatmap showing the frequency of Cys-creating, Cys-eliminating and other types of amino acid changes in different protein domains. cb, calcium binding; EGF, epidermal growth factor; LTBP, latent transforming growth factor β binding protein; TGFBP, transforming growth factor β binding protein.
Figure 4
Figure 4
Genotype–phenotype analysis of patients with and without MSP. (A) Comparison of type of mutation, amino acid change, protein domain and mutation sites in patients with EL alone or EL complicated by MSP. (B) Comparison of mutation spectrum by cluster analysis in patients with EL alone or EL complicated by MSP. Heatmap of fibrillin-1 mutations shows the number of missense mutations per exons and splicing mutations per introns. Exon 26 is marked by a red asterisk. Cys, cysteine; EL, ectopia lentis; EL − MSP, patients with EL but not MSP; EL+ MSP, patients with EL and MSP; EX, exon; Cys, MSP, microspherophakia. cb, calcium binding; EGF, epidermal growth factor; LTBP, latent transforming growth factor β binding protein; TGFBP, transforming growth factor β binding protein.

References

    1. Sakai LY, Keene DR. Fibrillin protein pleiotropy: acromelic dysplasias. Matrix Biol 2019;80:6–13. 10.1016/j.matbio.2018.09.005
    1. Pyeritz RE. Marfan syndrome: improved clinical history results in expanded natural history. Genet Med 2019;21:1683–90. 10.1038/s41436-018-0399-4
    1. Faivre L, Collod-Beroud G, Child A, et al. . Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands. J Med Genet 2008;45:384–90. 10.1136/jmg.2007.056382
    1. Loeys BL, Dietz HC, Braverman AC, et al. . The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47:476–85. 10.1136/jmg.2009.072785
    1. Maumenee IH. The eye in the Marfan syndrome. Trans Am Ophthalmol Soc 1981;79:684–733.
    1. Hoffman RS, Snyder ME, Devgan U, et al. . Management of the subluxated crystalline lens. J Cataract Refract Surg 2013;39:1904–15. 10.1016/j.jcrs.2013.09.005
    1. Richards S, Aziz N, Bale S, et al. . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. Genet Med 2015;17:405–23. 10.1038/gim.2015.30
    1. Groth KA, Von Kodolitsch Y, Kutsche K, et al. . Evaluating the quality of Marfan genotype-phenotype correlations in existing FBN1 databases. Genet Med 2017;19:772–7. 10.1038/gim.2016.181
    1. Faivre L, Collod-Beroud G, Loeys BL, et al. . Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet 2007;81:454–66. 10.1086/520125
    1. Nijbroek G, Sood S, McIntosh I, et al. . Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet 1995;57:8–21.
    1. De Maria A, Wilmarth PA, David LL, et al. . Proteomic analysis of the bovine and human ciliary zonule. Invest Ophthalmol Vis Sci 2017;58:573–85. 10.1167/iovs.16-20866
    1. Li J, Jia X, Li S, et al. . Mutation survey of candidate genes in 40 Chinese patients with congenital ectopia lentis. Mol Vis 2014;20:1017–24.
    1. Fuchs J, Rosenberg T. Congenital ectopia lentis. A Danish national survey. Acta Ophthalmol Scand 1998;76:20–6. 10.1034/j.1600-0420.1998.760105.x
    1. Hing S, Speedwell L, Taylor D. Lens surgery in infancy and childhood. Br J Ophthalmol 1990;74:73–7. 10.1136/bjo.74.2.73
    1. Adès LC, Holman KJ, Brett MS, et al. . Ectopia lentis phenotypes and the FBN1 gene. Am J Med Genet A 2004;126A:284–9. 10.1002/ajmg.a.20605
    1. Sakai LY, Keene DR, Renard M, et al. . Fbn1: the disease-causing gene for Marfan syndrome and other genetic disorders. Gene 2016;591:279–91. 10.1016/j.gene.2016.07.033
    1. Hirani R, Hanssen E, Gibson MA. Ltbp-2 specifically interacts with the amino-terminal region of fibrillin-1 and competes with LTBP-1 for binding to this microfibrillar protein. Matrix Biol 2007;26:213–23. 10.1016/j.matbio.2006.12.006
    1. Schrijver I, Liu W, Brenn T, et al. . Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet 1999;65:1007–20. 10.1086/302582
    1. Whiteman P, Handford PA. Defective secretion of recombinant fragments of fibrillin-1: implications of protein misfolding for the pathogenesis of Marfan syndrome and related disorders. Hum Mol Genet 2003;12:727–37. 10.1093/hmg/ddg081
    1. Reinhardt DP, Ono RN, Notbohm H, et al. . Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis. A potential disease-causing mechanism in Marfan syndrome. J Biol Chem 2000;275:12339–45. 10.1074/jbc.275.16.12339
    1. Faivre L, Collod-Beroud G, Callewaert B, et al. . Pathogenic FBN1 mutations in 146 adults not meeting clinical diagnostic criteria for Marfan syndrome: further delineation of type 1 fibrillinopathies and focus on patients with an isolated major criterion. Am J Med Genet A 2009;149A:854–60. 10.1002/ajmg.a.32809
    1. Collod-Béroud G, Le Bourdelles S, Ades L, et al. . Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat 2003;22:199–208. 10.1002/humu.10249
    1. Katzke S, Booms P, Tiecke F, et al. . TGGE screening of the entire FBN1 coding sequence in 126 individuals with Marfan syndrome and related fibrillinopathies. Hum Mutat 2002;20:197–208. 10.1002/humu.10112
    1. Zhao J-H, Jin T-B, Liu Q-B, et al. . Ophthalmic findings in a family with early-onset isolated ectopia lentis and the p.Arg62Cys mutation of the fibrillin-1 gene (FBN1). Ophthalmic Genet 2013;34:21–6. 10.3109/13816810.2012.718029
    1. Yu R, Lai Z, Zhou W, et al. . Recurrent FBN1 mutation (R62C) in a Chinese family with isolated ectopia lentis. Am J Ophthalmol 2006;141:1136–8. 10.1016/j.ajo.2005.12.044
    1. Aragon-Martin JA, Ahnood D, Charteris DG, et al. . Role of ADAMTSL4 mutations in FBN1 mutation-negative ectopia lentis patients. Hum Mutat 2010;31:E1622–31. 10.1002/humu.21305
    1. Biggin A, Holman K, Brett M, et al. . Detection of thirty novel FBN1 mutations in patients with Marfan syndrome or a related fibrillinopathy. Hum Mutat 2004;23:99. 10.1002/humu.9207
    1. Zeng Y, Li J, Li G, et al. . Correction of the Marfan syndrome pathogenic FBN1 mutation by base editing in human cells and heterozygous embryos. Mol Ther 2018;26:2631–7. 10.1016/j.ymthe.2018.08.007
    1. Loeys B. The search for genotype/phenotype correlation in Marfan syndrome: to be or not to be? Eur Heart J 2016;37:3291–3. 10.1093/eurheartj/ehw154
    1. Chan RT-Y, Collin HB. Microspherophakia. Clin Exp Optom 2002;85:294–9. 10.1111/j.1444-0938.2002.tb03085.x
    1. Kumar B, Chandler HL, Plageman T, et al. . Lens stretching modulates lens epithelial cell proliferation via YAP regulation. Invest Ophthalmol Vis Sci 2019;60:3920–9. 10.1167/iovs.19-26893
    1. Adès LC, Sullivan K, Biggin A, et al. . Fbn1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited. Am J Med Genet A 2006;140:1047–58. 10.1002/ajmg.a.31202
    1. Khokhar S, Pillay G, Sen S, et al. . Clinical spectrum and surgical outcomes in spherophakia: a prospective interventional study. Eye 2018;32:527–36. 10.1038/eye.2017.229

Source: PubMed

3
Tilaa